Dalrada settles IBS default claims for $20,000, terminating financing documents and releasing liens

Dalrada Technology Group, Inc.

Dalrada, Genefic subsidiaries and CEO Brian Bonar settled with IBS Equity Fund III and IBS Private Credit Fund IV for a $20,000 lump sum on Oct. 2, 2026.
IBS had demanded about $1,162,246 in fees and charges and asserted defaults; the $20,000 settlement covers all asserted amounts.
At closing, MGA, MCSPA, secured promissory note, pre-funded warrant, corporate and personal guaranties, pledges and account control agreements terminated; IBS liens released.
IBS withdrew its default and audit notices, closed account 6723030230, and a termination statement was filed with the Wyoming Secretary of State.
IBS confirmed it holds no shares or warrants and no amounts remain owing by Dalrada or its subsidiaries after the settlement.

item 1.01 item 1.02 item 8.01 item 2.04 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.